Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04091737 · ClinicalTrials.gov registry record · Phase 1
CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease
A Phase 1 study, sponsored by CSL Behring.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT04091737 is a Phase 1 study that was terminated before completion, run by CSL Behring. The registered enrollment target is 1 participants.
The verdict
NCT04091737, a Phase 1 study, was terminated before completion, sponsored by CSL Behring.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a phase 1 pilot study of CSL200 in adult subjects with severe sickle cell disease. The primary objectives of this study are to evaluate the safety of the following: collection of CD34+ hematopoietic stem / progenitor cells by apheresis after mobilization with plerixafor, reduced intensity conditioning with melphalan, and administration of CSL200.
Interventions
- BIOLOGICAL Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-10-02 |
| Est. Completion | 2021-05-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04091737
The ClinicalTrials.gov registry entry for NCT04091737 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734 is the first listed.
NCT04091737 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04091737 about?
NCT04091737 is a clinical study titled "CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease". This is a phase 1 pilot study of CSL200 in adult subjects with severe sickle cell disease. The primary objectives of this study are to evaluate the safety of the following: collection of CD34+ hematopoietic stem / progenitor cells by apheresis after mobilization with plerixafor, reduced intensity co...
What is the current status of trial NCT04091737?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2019-10-02. Estimated completion is 2021-05-05.
What interventions are being tested in trial NCT04091737?
The interventions under investigation include: Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04091737?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.